Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RETAIN BLADDER
NCT02710734Phase 2Completed
- Sponsor
- Fox Chase Cancer Center
- Start
- Feb 2016
- Primary completion
- Nov 2025
- Modality
- Targeted Liposomes, Orthosteric Ligands, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label trial of methotrexate, vinblastine, pegylated liposomal doxorubicin and Cisplatin micelle injection (HA132) in urothelial carcinoma of the bladder (UC) (4 arms), sponsored by Fox Chase Cancer Center. Primary endpoint: Metastasis-free survival at 2 years. Started Feb 2016; status: completed.
02
Drugs
methotrexatevinblastinepegylated liposomal doxorubicinCisplatin micelle injection (HA132)
03
Conditions
urothelial carcinoma of the bladder (UC)
Beyond the preview
Go deeper on NCT02710734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02710734.